Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dynavax (DVAX – Research Report), Eagle Pharmaceuticals (EGRX – Research Report) and FibroGen (FGEN – Research Report).
Dynavax (DVAX)
In a report issued on August 23, Matt Phipps from William Blair reiterated a Buy rating on Dynavax. The company’s shares closed last Friday at $17.17, close to its 52-week high of $18.13.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dynavax with a $19.50 average price target, implying a 7.9% upside from current levels. In a report issued on August 23, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.
See today’s analyst top recommended stocks >>
Eagle Pharmaceuticals (EGRX)
In a report issued on August 25, Tim Lugo from William Blair maintained a Buy rating on Eagle Pharmaceuticals. The company’s shares closed last Friday at $48.00.
According to TipRanks.com, Lugo is a 4-star analyst with an average return of
Eagle Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $50.00.
FibroGen (FGEN)
In a report issued on August 25, Andy Hsieh from William Blair reiterated a Hold rating on FibroGen. The company’s shares closed last Friday at $11.45, close to its 52-week low of $11.32.
According to TipRanks.com, Hsieh is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for FibroGen with a $21.86 average price target, which is a 90.6% upside from current levels. In a report issued on August 10, H.C. Wainwright also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DVAX:
- William Blair Believes Beyondspring (BYSI) Still Has Room to Grow
- William Blair Thinks Axsome Therapeutics’ Stock is Going to Recover
- Pieris Pharmaceuticals (PIRS) Gets a Buy Rating from William Blair
- William Blair Maintains Their Buy Rating on Adamas Pharmaceuticals (ADMS)
- BeyondSpring: Analyst Sees Little Trouble in Big China
